Complement testing in the clinical laboratory.

Complement system complement deficiency complement dysregulation laboratory testing

Journal

Critical reviews in clinical laboratory sciences
ISSN: 1549-781X
Titre abrégé: Crit Rev Clin Lab Sci
Pays: England
ID NLM: 8914816

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 9 5 2021
medline: 10 11 2021
entrez: 8 5 2021
Statut: ppublish

Résumé

The complement system is the human's first line of defense against microbial pathogens because of its important housekeeping and infection/inflammation roles. It is composed of a series of soluble and cell-bound proteins that are activated in a cascade effect, similar to the coagulation pathways. There are different pattern recognizing molecules that activate the complement system in response to stimuli or threats, acting through three initiation pathways: classical, lectin, and alternative. All three activation pathways converge at the C3 component and share the terminal pathway. The main outputs of the complement system action are lytic killing of microbes, the release of pro-inflammatory anaphylatoxins, and opsonization of targets. Laboratory testing is relevant in the setting of suspected complement deficiencies, as well as in the emerging number of diseases related to dysregulation (over-activation) of complement. Most common assays measure complement lytic activity and the different complement component concentrations. Specialized testing includes the evaluation of autoantibodies against complement components, activation fragments, and genetic studies. In this review, we cover laboratory testing for complement and the conditions with complement involvement, as well as current challenges in the field.

Identifiants

pubmed: 33962553
doi: 10.1080/10408363.2021.1907297
doi:

Substances chimiques

Autoantibodies 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-478

Auteurs

Maria Alice V Willrich (MAV)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Karin M P Braun (KMP)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Ann M Moyer (AM)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

David H Jeffrey (DH)

Exsera Biolabs, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Ashley Frazer-Abel (A)

Exsera Biolabs, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH